Nutrition and Dietary Supplements (Dec 2023)

Cross-Sectional Survey of Adulterated Sexual Enhancement Products Sold in the Sacramento Area of California

  • Fischer T,
  • Tucker J,
  • Li C,
  • Min K,
  • Xu D,
  • Upjohn LR,
  • Kumar M

Journal volume & issue
Vol. Volume 15
pp. 111 – 120

Abstract

Read online

Tessa Fischer,1,2 Jenna Tucker,1,2 Charlie Li,3 Kyungmi Min,3 Dadong Xu,3 Laurence R Upjohn,1 Madhur Kumar1 1Food and Drug Branch, California Department of Public Health, Sacramento, CA, USA; 2California Epidemiologic Investigation Service (Cal EIS) Fellowship Program, California Department of Public Health, Sacramento, CA, USA; 3Food and Drug Laboratory Branch, California Department of Public Health, Richmond, CA, USACorrespondence: Madhur Kumar, Food and Drug Branch, California Department of Public Health, 1500 Capitol Avenue, MS 7602, Sacramento, CA, 95814, USA, Email [email protected]: The Food and Drug Administration (FDA) has warned against tainted products for sexual enhancement containing prescription phosphodiesterase-5 (PDE5) inhibitors marketed as dietary supplements. The California Department of Public Health (CDPH)’s Food and Drug Branch (FDB) initiated a study to assess the presence of such adulterated products, specifically to identify the presence of PDE5 inhibitors in dietary supplements marketed for sexual enhancement, sampled at local retail locations.Methods: A convenience sample of products marketed as sexual enhancement dietary supplements was purchased from retail stores, within a 15-mile radius of downtown Sacramento, California. Samples were submitted to the Food and Drug Laboratory Branch (FDLB) and screened for 19 different PDE5 inhibitors using liquid chromatography-mass spectrometry. Samples were collected and analyzed from 2016 to 2018.Results: One hundred and two different products were purchased from 28 different retail locations. Sixty-seven percent were found to be adulterated with at least one PDE5 inhibitor. Of the positive samples, 40% were found to contain one PDE5 inhibitor and 60% were found to contain two or more. Sildenafil was the most common PDE5 inhibitor identified (74%), followed by tadalafil (59%). Eighteen percent of the tested samples had been associated with previous FDA warnings listed in their Tainted Products Database. Of these warning-associated samples, 72% were found to contain PDE5 inhibitors and 46% of these contained at least one of the same adulterants reported by the FDA.Conclusion: FDA reports and warnings have focused on dietary supplements found online or through screenings of international mail shipments. FDB results add to FDA findings by demonstrating that such adulterated products marketed for sexual enhancement are also sold at retail locations in California. These products have the potential to cause severe adverse health effects and therefore, it is essential to raise awareness of this significant public health concern.Keywords: dietary supplements, sexual enhancement products, adulteration

Keywords